https://doi.org/10.55788/11423011
Wearable devices, such as fitness trackers, are an easy-to-use instrument to collect objective data related to physical activity, which is an important lifestyle factor for improving long-term health, especially in patients with rheumatic musculoskeletal disorders due to their increased cardiovascular risk. In the general population, wearable fitness trackers are increasingly popular to assess physical activity and get motivational cues.
A meta-analysis presented by Prof. Luca Quartuccio (University of Udine, Italy) aimed to evaluate wearable devices in patients with both non-inflammatory (i.e. fibromyalgia, osteoarthritis) and inflammatory (i.e. chronic inflammatory arthropathies, systemic autoimmune disorders) rheumatic diseases as a means to assess physical activity [1]. The researchers explored both daily steps and moderate-to-vigorous physical training as assessed with fitness trackers. The comparison of both parameters to reference values for healthy people was defined as a secondary outcome. According to a literature review, 7,000 daily steps were recommended [2]. The reference value for moderate-to-vigorous physical training was 150 min/week and was derived from WHO guidelines [3].
An overall of 51 studies, including 7,488 participants, were included. Participants reached the recommended threshold for moderate-to-vigorous physical training but failed the goal of 7,000 daily steps. Participants with rheumatic conditions reported 1092.6 fewer daily steps compared with the reference value. An even higher difference was reported in participants with autoimmune disease (1865.9 fewer steps) and osteoarthritis (1385.6 fewer steps), whereas patients with fibromyalgia and inflammatory arthropathies fared significantly better. Overall, younger people had a higher level of physical activity (6796.1 vs 5431.9 in the elderly).
The authors concluded that patients with rheumatic musculoskeletal diseases have an alarmingly low level of physical activity. The underlying diseases did not seem to impair strength but rather decrease tolerance or motivation for physical efforts. Wearable fitness trackers are an easy-to-use tool that should be integrated into future studies on physical activity. “The use of wearable devices may itself stimulate physical activity in patients with rheumatic musculoskeletal diseases,” Prof. Quartuccio said.
- Ocagli H, et al. Usefulness of wearable devices to assess physical activity in non-inflammatory and inflammatory rheumatic disease: a systematic review and meta-analysis. POS0163, EULAR 2022 Congress, 1–4 June, Copenhagen,
- Tudor-Locke C, et al. Int J Behav Nutr Phys Act. 2011;8:79.
- Bull FC, et al. Br J Sports Med. 2020;54:1451–62.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« High prevalence of fibromyalgia in patients with inflammatory bowel disease Next Article
Letter from the Editor »
« High prevalence of fibromyalgia in patients with inflammatory bowel disease Next Article
Letter from the Editor »
Table of Contents: EULAR 2022
Featured articles
Late-Breaking Oral Abstracts
TYK2 inhibition: the future of treating lupus erythematosus?
Psoriatic arthritis: significant improvement with bimekizumab
Baricitinib could open the door to oral treatment for juvenile idiopathic arthritis
Sarilumab for polymyalgia rheumatica led to sustained remission and fewer flares
Spotlight on Rheumatoid Arthritis
Comorbid depression comes with a profoundly higher mortality risk in RA
Preventive treatment with methotrexate benefits pre-RA patients with arthralgia
Risk factors for dementia in RA patients discovered
VTE in global registry data more common in JAK inhibitor-treated RA patients
Spondyloarthropathies – Novel Developments
How to treat enthesitis in 2022
Baseline cardiovascular risk linked to higher rates of MACE in PsA and PsO patients receiving tofacitinib
Treat-to-target dose reduction effective in spondyloarthritis
A novel oral treatment possibility for non-radiographic axSpA on the horizon
Many RA and PsA patients have problems with their sex life
What Is Hot in Osteoarthritis?
New treatments in osteoarthritis
OA associated with alcohol and drug abuse
Body mass index increase associated with structural changes in knee OA
What Is New in Lupus and Scleroderma
Inhibition of Bruton’s tyrosine kinase: a new way of approaching SLE?
Pregnancies in SLE: many complications for mothers and their unborn children
Lupus nephritis: Efficient treatment may reduce the risk of kidney disease advancement
Antifibrotic therapy with nintedanib is beneficial for patients with negative prognostic factors
Best of the Posters
Alarmingly low activity in patients with non-inflammatory and inflammatory rheumatic disease
High prevalence of fibromyalgia in patients with inflammatory bowel disease
Related Articles
October 23, 2019
Ustekinumab is safe and effective in ulcerative colitis: 2-year data
October 27, 2021
Upadacitinib efficacious and safe as maintenance therapy for UC
April 14, 2020
Increased risk of small bowel cancer in IBD
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com